EA201492208A1 - Композиция в водной среде, включающая по меньшей мере одну гиалуроновую кислоту и по меньшей мере одну водорастворимую соль октасульфата сахарозы - Google Patents

Композиция в водной среде, включающая по меньшей мере одну гиалуроновую кислоту и по меньшей мере одну водорастворимую соль октасульфата сахарозы

Info

Publication number
EA201492208A1
EA201492208A1 EA201492208A EA201492208A EA201492208A1 EA 201492208 A1 EA201492208 A1 EA 201492208A1 EA 201492208 A EA201492208 A EA 201492208A EA 201492208 A EA201492208 A EA 201492208A EA 201492208 A1 EA201492208 A1 EA 201492208A1
Authority
EA
Eurasian Patent Office
Prior art keywords
less
composition
hyaluronic acid
salt
vodorable
Prior art date
Application number
EA201492208A
Other languages
English (en)
Inventor
Эстелль Пирон
Жереми Бон Бетамп
Original Assignee
Лаборатуар Виваси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Виваси filed Critical Лаборатуар Виваси
Publication of EA201492208A1 publication Critical patent/EA201492208A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Изобретение относится к композиции, включающей по меньшей мере одну гиалуроновую кислоту сшитой или несшитой структуры или одну из ее солей и по меньшей мере одну водорастворимую соль октасульфата сахарозы, способам получения упомянутой смеси, а также применению упомянутой смеси для формулирования состава смеси для вискосапплементарной терапии или формулирования смеси для заполнения морщин или формулирования фармацевтической смеси.
EA201492208A 2012-06-13 2013-06-13 Композиция в водной среде, включающая по меньшей мере одну гиалуроновую кислоту и по меньшей мере одну водорастворимую соль октасульфата сахарозы EA201492208A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659140P 2012-06-13 2012-06-13
FR1255543A FR2991876B1 (fr) 2012-06-13 2012-06-13 Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
PCT/FR2013/051380 WO2013186493A2 (fr) 2012-06-13 2013-06-13 Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate

Publications (1)

Publication Number Publication Date
EA201492208A1 true EA201492208A1 (ru) 2015-04-30

Family

ID=46785648

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492208A EA201492208A1 (ru) 2012-06-13 2013-06-13 Композиция в водной среде, включающая по меньшей мере одну гиалуроновую кислоту и по меньшей мере одну водорастворимую соль октасульфата сахарозы

Country Status (17)

Country Link
US (1) US9314530B2 (ru)
EP (1) EP2861301B1 (ru)
JP (1) JP6178414B2 (ru)
KR (1) KR20150023468A (ru)
CN (1) CN104394934B (ru)
AU (1) AU2013276343B2 (ru)
BR (1) BR112014029510A2 (ru)
CA (1) CA2876057A1 (ru)
EA (1) EA201492208A1 (ru)
ES (1) ES2728686T3 (ru)
FR (1) FR2991876B1 (ru)
IL (1) IL235776A0 (ru)
MX (1) MX354544B (ru)
PL (1) PL2861301T3 (ru)
SG (1) SG11201407857SA (ru)
TR (1) TR201907427T4 (ru)
WO (1) WO2013186493A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2837626T3 (es) 2013-07-10 2021-07-01 Matrix Biology Inst Composiciones de hialuronano con alta elasticidad y usos de las mismas
US9421198B2 (en) 2013-07-30 2016-08-23 Teoxane Composition comprising hyaluronic acid and mepivacaine
FR3015290B1 (fr) * 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine
CN106659663A (zh) * 2014-06-30 2017-05-10 纽璀克斯技术公司 控制影响角化细胞和/或成纤维细胞和真皮的皮肤失调和皮肤老化的组合产品和美容组合物
FR3032617B1 (fr) * 2015-02-16 2018-03-16 Kylane Laboratoires Sa Procede de preparation d un hydrogel injectable; hydrogel obtenu; utilisation de l hydrogel obtenu
FR3036035B1 (fr) 2015-05-11 2018-10-05 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
CN104926889A (zh) * 2015-05-24 2015-09-23 广西师范学院 蔗糖硫酸酯铜银类化合物及其制作方法和用途
PT3352766T (pt) 2015-09-24 2022-03-22 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e processos para o seu uso
FR3044557B1 (fr) * 2015-12-07 2017-12-01 Benedicte Vincente Gavard Molliard Tauzin Nouvelle composition injectable; procede de preparation de ladite composition; utilisation de ladite composition
WO2017102001A1 (fr) 2015-12-16 2017-06-22 Vplus International Sa Composition d'acide hyaluronique pour injections peniennes
FR3047666A1 (fr) * 2016-02-15 2017-08-18 Benedicte Vincente Gavard Molliard Tauzin Composition injectable; procede de preparation de ladite composition; utilisation de ladite composition
FR3058064B1 (fr) 2016-10-28 2020-08-07 Lab Vivacy Composition a base d'acide hyaluronique comprenant de la mepivacaine
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
US20200093852A1 (en) * 2016-12-13 2020-03-26 Keats NELMS Methods of Treating Ocular Disorders
FR3109153B1 (fr) 2020-04-10 2022-07-15 Teoxane SA Compositions à base d’au moins deux glycosaminoglycanes
KR102664134B1 (ko) * 2023-11-23 2024-05-10 한국콜마주식회사 히알루론산 및 이의 유도체를 포함하는 화장료 조성물

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2715091A (en) 1949-11-28 1955-08-09 Nat Res Dev Dextran sulfate as anticoagulant, process of preparing same, and sterile solution thereof
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
DK505488D0 (da) 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5916880A (en) 1987-12-21 1999-06-29 Bukh Meditec A/S Reduction of skin wrinkling using sulphated sugars
DK86492D0 (da) 1992-06-30 1992-06-30 Bukh Meditec Laegemiddel
AU4941297A (en) 1996-11-15 1998-06-10 Dumex-Alpharma A/S A method for promoting tissue repair
JP2000178196A (ja) * 1998-12-11 2000-06-27 Seikagaku Kogyo Co Ltd 新規ヒアルロニダーゼ阻害剤及び外用剤
GB9902412D0 (en) 1999-02-03 1999-03-24 Fermentech Med Ltd Process
JP2005521629A (ja) * 2001-06-25 2005-07-21 デピユイ・インターナシヨナル・リミテツド 関節炎の関節を治療するためのグリコサミノグリカンとヒアルロニダーゼ阻害剤を含んで成る組成物
WO2003038054A2 (en) * 2001-10-31 2003-05-08 New York University Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
AUPS052802A0 (en) 2002-02-15 2002-03-07 Praxis Pharmaceuticals International Pty Ltd Carbohydrate-based anti-wrinkle and tissue remodelling compounds
US20080003258A1 (en) 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
EP1560588B1 (en) 2002-10-16 2011-09-21 ArthroDynamic Technologies, Animal Health Division, Inc. Treatment for traumatic synovitis and damaged articular cartilage
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
GB0329907D0 (en) 2003-12-23 2004-01-28 Innomed Ltd Compositions
FR2865737B1 (fr) 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible
WO2006017752A2 (en) 2004-08-05 2006-02-16 Ivax Corporation Sulfated oligosaccharides
EP1781305A2 (en) * 2004-08-13 2007-05-09 Angiotech International Ag Compositions and methods using hyaluronic acid and hyaluronidase inhibitors
WO2008011836A2 (es) 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
WO2008020495A1 (fr) * 2006-08-15 2008-02-21 Tokyo Cemical Industry Co., Ltd. Nouvel inhibiteur
FR2918276B1 (fr) 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
ITMI20072237A1 (it) 2007-11-27 2009-05-28 Sigea Srl Esteri misti butirrico-formico di polisaccaridi acidi, loro preparazione ed uso come dermocosmetici
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
FR2924615B1 (fr) 2007-12-07 2010-01-22 Vivacy Lab Hydrogel cohesif biodegradable.
FR2953522B1 (fr) 2009-12-07 2012-03-09 Fabre Pierre Dermo Cosmetique Sucrose octasulfates de zinc, leur preparation et leurs applications pharmaceutiques et cosmetiques
US20110171310A1 (en) 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
FR2956322A1 (fr) 2010-02-17 2011-08-19 Urgo Lab Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie.
WO2012008722A2 (ko) * 2010-07-12 2012-01-19 신풍제약 주식회사 조직 증강용 충전 조성물
FR2983483B1 (fr) 2011-12-02 2014-11-14 Vivacy Lab Procede de substitution et reticulation simultanees d'un polysaccharide via ses fonctions hydroxyles

Also Published As

Publication number Publication date
JP2015525099A (ja) 2015-09-03
MX354544B (es) 2018-03-09
BR112014029510A2 (pt) 2017-06-27
SG11201407857SA (en) 2015-02-27
KR20150023468A (ko) 2015-03-05
ES2728686T3 (es) 2019-10-28
FR2991876B1 (fr) 2014-11-21
TR201907427T4 (tr) 2019-06-21
PL2861301T3 (pl) 2020-08-24
FR2991876A1 (fr) 2013-12-20
MX2014013949A (es) 2015-05-11
EP2861301B1 (fr) 2019-02-20
CA2876057A1 (fr) 2013-12-19
JP6178414B2 (ja) 2017-08-09
CN104394934B (zh) 2018-01-09
WO2013186493A2 (fr) 2013-12-19
AU2013276343B2 (en) 2017-06-15
US20140005140A1 (en) 2014-01-02
AU2013276343A1 (en) 2014-12-04
CN104394934A (zh) 2015-03-04
WO2013186493A3 (fr) 2014-05-08
IL235776A0 (en) 2015-01-29
EP2861301A2 (fr) 2015-04-22
US9314530B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
EA201492208A1 (ru) Композиция в водной среде, включающая по меньшей мере одну гиалуроновую кислоту и по меньшей мере одну водорастворимую соль октасульфата сахарозы
CY1120334T1 (el) Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
WO2015095811A3 (en) Combination therapy with neoantigen vaccine
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
NZ732777A (en) Ionizable cationic lipid for rna delivery
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
TR201909447T4 (tr) Aramkol tuzları.
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA202090662A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
CL2013000866A1 (es) Sales cristalinas oxalato y fosfato del conjugado naloxolpolietilenglicol; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento del dolor.
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила